Alexion specializes in drugs used to treat illnesses that affect less than 200,000 people. Its drug, Soliris, is used to reduce symptoms of paroxysmal nocturnal hemoglobinuria, a blood disease, and atypical hemolytic uremic syndrome, a kidney disease.
The suit alleged that, between January 2014 and May 2017, Alexion’s growth of the Soliris market in other countries was obtained through illegal and unethical sales practices. It ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.